Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
about
Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series.Peptide inhibitor of complement C1 modulates acute intravascular hemolysis of mismatched red blood cells in rats.Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.Incidental Discovery of Anti-IH in a Patient Planned for Caesarean Section and it's RepercussionsContribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease
P2860
Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Life-threatening delayed hyper ...... lizumab followed by rituximab.
@en
Life-threatening delayed hyper ...... lizumab followed by rituximab.
@nl
type
label
Life-threatening delayed hyper ...... lizumab followed by rituximab.
@en
Life-threatening delayed hyper ...... lizumab followed by rituximab.
@nl
prefLabel
Life-threatening delayed hyper ...... lizumab followed by rituximab.
@en
Life-threatening delayed hyper ...... lizumab followed by rituximab.
@nl
P2093
P2860
P356
P1433
P1476
Life-threatening delayed hyper ...... lizumab followed by rituximab.
@en
P2093
Chaiyaporn Boonchalermvichian
Howard A Liebman
Ilene C Weitz
Ira A Shulman
Mark Boonyasampant
P2860
P304
P356
10.1111/TRF.13144
P577
2015-05-18T00:00:00Z